Order Article Reprints

Yaşar S, Kadıoğlu A, Akyildiz A, Sever N, Büyükbayram ME, Bilici M, Karaman E, Uzun M, Bardakcı M, Koseoglu C, et al. “Pre-Treatment“ and “Post-Treatment” Systemic Inflammatory Markers: Is There Any Prognostic Role for Metastatic Cervical Cancer on Bevacizumab Containing Treatment? Medicina. 2025; 61(6):1100. https://doi.org/10.3390/medicina61061100

Yaşar, Serkan, Ahmet Kadıoğlu, Arif Akyildiz, Nadiye Sever, Mehmet Emin Büyükbayram, Mehmet Bilici, Elanur Karaman, Mehmet Uzun, Murat Bardakcı, Caglar Koseoglu, and et al. 2025. "“Pre-Treatment“ and “Post-Treatment” Systemic Inflammatory Markers: Is There Any Prognostic Role for Metastatic Cervical Cancer on Bevacizumab Containing Treatment?" Medicina 61, no. 6: 1100. https://doi.org/10.3390/medicina61061100

Yaşar, S., Kadıoğlu, A., Akyildiz, A., Sever, N., Büyükbayram, M. E., Bilici, M., Karaman, E., Uzun, M., Bardakcı, M., Koseoglu, C., Bilgetekin, I., İçli, M. C., Türkel, A., Arık, Z., Sarı, M., Yavuzsen, T., Sendur, M. A. N., Erturk, İ., & Dogan, M. (2025). “Pre-Treatment“ and “Post-Treatment” Systemic Inflammatory Markers: Is There Any Prognostic Role for Metastatic Cervical Cancer on Bevacizumab Containing Treatment? Medicina, 61(6), 1100. https://doi.org/10.3390/medicina61061100